Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470301 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
A Phase 1 study of Breast Cancer and Stage II Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT00470301 is a Phase 1 study of Breast Cancer and Stage II Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT00470301, a Phase 1 study of Breast Cancer and Stage II Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving tipifarnib together with combination chemotherapy may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with combination chemotherapy and to see how well they work in treating patients with stage II or stage III breast cancer.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG paclitaxel
- DRUG tipifarnib
Study Locations (7)
New York
- Mount Sinai Medical Center - New York
- Columbia University Medical Center - New York
- Weill Medical College of Cornell University - New York
- Albert Einstein College of Medicine - The Bronx
- Montefiore Medical Center - The Bronx
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470301
The ClinicalTrials.gov registry entry for NCT00470301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00470301 reports 7 study locations spanning 3 distinct geographic areas - top geographies include New York, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT00470301 about?
NCT00470301 is a clinical study titled "Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer". Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killi...
What is the current status of trial NCT00470301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-04. Estimated completion is 2013-09.
What conditions does trial NCT00470301 study?
This clinical trial studies the following conditions: Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer.
What interventions are being tested in trial NCT00470301?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin (DRUG), paclitaxel (DRUG), tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00470301?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00470301 being conducted?
This trial has 7 study locations across Florida, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.